Abstract
Nanotechnology has revolutionized the field of drug delivery, offering targeted, efficient, and controlled release of therapeutic agents. By employing nanocarriers such as liposomes, dendrimers, and nanoparticles, drugs can be delivered directly to diseased cells, reducing side effects and enhancing bioavailability. This paper explores the mechanisms, materials, and clinical advancements in nanotechnology-based drug delivery systems. It emphasizes how nanoscale materials can overcome biological barriers, enhance pharmacokinetics, and support personalized medicine approaches. The study also discusses regulatory challenges and future prospects in this evolving field.
All articles published in the Austra & Lian Journal of Basic Sciences are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license, authors retain full copyright of their work, and readers are free to share, copy, redistribute, adapt, and build upon the material in any medium or format, provided appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are clearly indicated. This open-access license promotes the widest possible dissemination and use of research outputs.